Matricelf plans a subsidiary to commercialize its Parkinson’s therapy platform. Discover what this move signals for regenerative medicine and neurology innovation.
Pierre Fabre Pharmaceuticals seeks an FDA path forward for tabelecleucel in EBV-positive PTLD after a Complete Response Letter. Discover what regulators may scrutinize next.
DarioHealth targets oral GLP-1 therapy support with behavioral digital tools. Discover how digital health platforms could reshape obesity and diabetes treatment.
FDA grants rare hearing to review Vanda Pharmaceuticals’ HETLIOZ jet lag application. Discover what this regulatory fight could mean for circadian medicine.
Insilico Medicine and Liquid AI unveil a lightweight AI model for drug discovery. Learn how smaller foundation models could reshape pharmaceutical research.
Genentech's obinutuzumab met all ALLEGORY phase III endpoints in SLE. What the remission and flare data mean for lupus treatment strategy.
Aisa Pharma’s AISA-021 shows promising Phase 2 signals in systemic sclerosis Raynaud’s. Discover what the RECONNOITER data could mean for future treatment.
Lone Star Funds acquires Lonza's CHI division in a carve-out reshaping pharma capsule supply. Read what this means for the CDMO market.
MindWalk launches B Cell Llama, a VHH nanobody platform for bispecific drug design. Peer-reviewed data raises key questions about function, immunogenicity, and AI.
Savara's molgramostim BLA faces no FDA adcom. Analysis of what the August 2026 PDUFA date means for autoimmune PAP treatment access. Read more.